ME01300B - Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja - Google Patents

Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja

Info

Publication number
ME01300B
ME01300B MEP-2011-87A MEP8711A ME01300B ME 01300 B ME01300 B ME 01300B ME P8711 A MEP8711 A ME P8711A ME 01300 B ME01300 B ME 01300B
Authority
ME
Montenegro
Prior art keywords
dosage form
fentanyl
amount
weight
mannitol
Prior art date
Application number
MEP-2011-87A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Derek Moe
Vikas Agarwal
Walid Habib
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34753002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01300(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of ME01300B publication Critical patent/ME01300B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-2011-87A 2003-12-31 2004-12-30 Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja ME01300B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53361903P 2003-12-31 2003-12-31
US61566504P 2004-10-04 2004-10-04
PCT/US2004/043703 WO2005065319A2 (en) 2003-12-31 2004-12-30 Generally linear effervescent oral fentanyl dosage form and methods of administering
EP04815716A EP1708686B1 (en) 2003-12-31 2004-12-30 Generally linear effervescent oral fentanyl dosage form and methods of administering

Publications (1)

Publication Number Publication Date
ME01300B true ME01300B (me) 2013-12-20

Family

ID=34753002

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2011-87A ME01300B (me) 2003-12-31 2004-12-30 Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja

Country Status (22)

Country Link
US (3) US20050142197A1 (OSRAM)
EP (1) EP1708686B1 (OSRAM)
JP (2) JP2007517054A (OSRAM)
KR (1) KR101184138B1 (OSRAM)
CN (1) CN102078310B (OSRAM)
AT (1) ATE498395T1 (OSRAM)
AU (1) AU2004311880B2 (OSRAM)
BR (1) BRPI0418228B8 (OSRAM)
CA (1) CA2548915C (OSRAM)
CY (1) CY1111458T1 (OSRAM)
DE (1) DE602004031462D1 (OSRAM)
DK (1) DK1708686T3 (OSRAM)
EA (1) EA010826B1 (OSRAM)
HR (1) HRP20110336T1 (OSRAM)
IL (1) IL176449A (OSRAM)
ME (1) ME01300B (OSRAM)
NO (1) NO338714B1 (OSRAM)
NZ (1) NZ548216A (OSRAM)
PL (1) PL1708686T3 (OSRAM)
PT (1) PT1708686E (OSRAM)
RS (1) RS51713B (OSRAM)
WO (1) WO2005065319A2 (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
BR0115382A (pt) 2000-10-30 2003-09-16 Euro Celtique Sa Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
ATE500821T1 (de) * 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US20050142197A1 (en) 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US7658945B2 (en) 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20060276501A1 (en) * 2005-05-25 2006-12-07 Transoral Pharmaceuticals, Inc. Solid compositions for treating middle-of-the-night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8357114B2 (en) * 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) * 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080090874A1 (en) * 2006-09-20 2008-04-17 Messina John C Jr Treatment of breakthrough pain in patients suffering from chronic low back pain
WO2008067549A2 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized zolpidem pharmaceutical compositions
US20090214442A1 (en) * 2006-12-01 2009-08-27 Cephalon, Inc. Oral Transmucosal Nicotine Dosage Form
AU2007328373A1 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
CA2677281C (en) * 2007-02-09 2019-10-29 Durect Corporation Transoral dosage forms comprising sufentanil and naloxone
WO2008133952A2 (en) * 2007-04-24 2008-11-06 Cephalon, Inc. Transmucosal treatment with fentanyl in patients with mucositis
NZ580967A (en) 2007-05-01 2012-04-27 Cephalon Inc Composition comprising a bile salt and an effervescent excipient component for transmucosal delivery of polypeptides
EP2182902B1 (en) * 2007-08-07 2015-01-07 Acelrx Pharmaceuticals, Inc. Compositions comprising sufentanil and triazolam for procedural sedation and analgesia using oral transmucosal dosage forms
ITMI20071971A1 (it) * 2007-10-10 2009-04-11 Altergon Sa Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010100414A1 (en) 2009-03-04 2010-09-10 Orexo Ab Abuse resistant formulation
AU2010244194B2 (en) * 2009-05-08 2014-12-04 Orexo Ab Composition for sustained drug delivery comprising geopolymeric binder
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
WO2012032337A2 (en) 2010-09-07 2012-03-15 Orexo Ab A transdermal drug administration device
US9320526B1 (en) * 2011-10-13 2016-04-26 Enteroptyx Punctum plug
SG11201407081PA (en) 2012-05-02 2014-11-27 Orexo Ab New alfentanil composition for the treatment of acute pain
WO2014145285A1 (en) * 2013-03-15 2014-09-18 Mylan Inc. Manufacturing process for effervescent dosage forms
US11058856B2 (en) 2014-12-23 2021-07-13 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
WO2018117855A1 (en) * 2016-12-20 2018-06-28 X-Ing As Effervescent lozenge
NO20171457A1 (no) * 2016-12-20 2018-06-21 X Ing As Effervesent sugetablett

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1262888A (en) * 1917-02-20 1918-04-16 Albert Westlake Mouth-tablet.
US1263888A (en) * 1918-01-10 1918-04-23 J T Vail Wave-motor.
US2887437A (en) 1956-08-22 1959-05-19 Pfizer & Co C Palatable vitamin tablet containing an amino acid
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3042531A (en) 1959-12-09 1962-07-03 Leslie Salt Company Method of making a compressed tablet
US3577490A (en) * 1967-10-02 1971-05-04 Miles Lab Effervescent tablet and process for making same
GB1212704A (en) 1967-11-21 1970-11-18 Prodotti Antibiotici Spa Vaginal suppositories
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
NL7302521A (en) 1973-02-23 1974-08-27 Foaming, effervescent capsules - contg. therapeutic agents for rectal and vaginal use
US3962417A (en) * 1974-03-27 1976-06-08 Howell Charles J Dentifrice
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4147768A (en) * 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
US4370160A (en) 1978-06-27 1983-01-25 Dow Corning Corporation Process for preparing silicone microparticles
US4187286A (en) * 1979-01-02 1980-02-05 G&W Laboratories, Inc. Contraceptive suppository
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
JPS58152809A (ja) * 1982-03-05 1983-09-10 Eisai Co Ltd 安定な発泡性「膣」坐剤
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4493848A (en) * 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
GB8410290D0 (en) * 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
US4613497A (en) * 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
GB8421226D0 (en) * 1984-08-21 1984-09-26 Int Conferences Ab Tooth cleaning tablet
US4639368A (en) * 1984-08-23 1987-01-27 Farmacon Research Corporation Chewing gum containing a medicament and taste maskers
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4687662A (en) * 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US5053396A (en) * 1985-08-27 1991-10-01 Blass David H Therapeutic composition
IT1209667B (it) * 1985-11-12 1989-08-30 Zambon Spa Composizione effeverscente adattivita' analgesica.
US4876039A (en) 1986-11-04 1989-10-24 Dow Corning Corporation Process for preparing silicone microparticles cured by a Michael addition reaction
IE873172L (en) 1986-12-29 1988-06-29 Harvard College Continuous process for producing a comestible tablet
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
FR2633181B1 (fr) 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
DE3838431A1 (de) * 1988-11-12 1990-05-17 Bayer Ag Ibuprofen-brausezubereitungen
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
WO1992018143A1 (en) * 1991-04-15 1992-10-29 Applied Microbiology, Inc. Pharmaceutical compositions against gastric disorders
TW212139B (OSRAM) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
IT1251114B (it) 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
DE4139883A1 (de) 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Verfahren zur herstellung bioadhaesiver arzneimittel
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
JP3021661B2 (ja) * 1994-03-07 2000-03-15 セラテック・インコーポレーテッド 薬剤含有接着複合体の経皮放出デバイス
AU696855B2 (en) * 1994-03-18 1998-09-17 Shire Laboratories, Inc. Emulsified drug delivery systems
WO1995028144A1 (en) * 1994-04-13 1995-10-26 Ciba-Geigy Ag Temporally controlled drug delivery systems
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5550861A (en) * 1994-09-27 1996-08-27 Novalink Technologies, Inc. Modular PCMCIA modem and pager
CA2160423A1 (en) * 1994-11-02 1996-05-03 Hemant N. Joshi Salts of nefazodone having improved dissolution rates
FR2729858B1 (fr) 1995-01-30 1997-04-18 Mission Soc Civ Composition effervescente a base de polyvinylpyrrolidone iodee et utilisation pour la desinfection
FR2732217B1 (fr) 1995-03-29 1997-06-06 Hesnard Xavier Forme d'administration solide a usage oral
US5656284A (en) * 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
CA2218370C (en) 1995-07-31 2006-10-03 Gerhard Gergely Chewable tablet with effervescent action
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
WO1997017067A1 (en) * 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
GB9523136D0 (en) * 1995-11-11 1996-01-10 Procter & Gamble Silicone-containing powders
GB2307857B (en) 1995-12-04 1999-01-27 Euro Celtique Sa An effervescent formulation
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
DE19606151C2 (de) * 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
DE19618543C2 (de) * 1996-05-08 1998-07-02 Ivoclar Ag Polymerisationsgerät
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
ES2210529T3 (es) 1996-05-17 2004-07-01 MERCK & CO., INC. Formulacion de bisfosfonato efervescente.
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US20010006677A1 (en) * 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
CA2284132C (en) * 1997-04-01 2004-09-07 Cima Labs Inc. Blister package and packaged tablet
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
DE59706616D1 (de) * 1997-10-27 2002-04-18 Gergely Gerhard Brausezubereitung mit Pflanzenextrakt
ATE246506T1 (de) 1998-03-11 2003-08-15 Grelan Pharmaceutical Co Darmlösliche sprudelnde zusammensetzungen
US6576250B1 (en) * 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6326384B1 (en) * 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002045713A2 (en) * 2000-12-04 2002-06-13 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment
AU2004208644B2 (en) 2003-01-31 2009-07-23 Orexo Ab A rapid-acting pharmaceutical composition
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
ATE500821T1 (de) 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US20070036853A1 (en) * 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US20050142197A1 (en) * 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
TWI387466B (zh) 2004-10-04 2013-03-01 Cima Labs Inc 一般線型起泡的口服吩坦尼（ｆｅｎｔａｎｙｌ）劑型及投藥方法

Also Published As

Publication number Publication date
JP2013100347A (ja) 2013-05-23
WO2005065319A3 (en) 2006-01-12
KR101184138B1 (ko) 2012-09-19
JP5685610B2 (ja) 2015-03-18
WO2005065319A2 (en) 2005-07-21
KR20060127944A (ko) 2006-12-13
RS51713B (sr) 2011-10-31
HK1100480A1 (en) 2007-09-21
EP1708686A2 (en) 2006-10-11
AU2004311880A1 (en) 2005-07-21
BRPI0418228B8 (pt) 2021-05-25
EP1708686B1 (en) 2011-02-16
EP1708686A4 (en) 2007-12-26
NO20063430L (no) 2006-09-15
NZ548216A (en) 2010-02-26
DE602004031462D1 (de) 2011-03-31
CN102078310B (zh) 2013-01-23
JP2007517054A (ja) 2007-06-28
US20050142197A1 (en) 2005-06-30
HRP20110336T1 (hr) 2011-07-31
PL1708686T3 (pl) 2011-08-31
US8092832B2 (en) 2012-01-10
CN102078310A (zh) 2011-06-01
US20110073518A1 (en) 2011-03-31
IL176449A0 (en) 2006-10-05
CA2548915A1 (en) 2005-07-21
EA200601253A1 (ru) 2006-12-29
CY1111458T1 (el) 2015-08-05
US7862832B2 (en) 2011-01-04
US20050169989A1 (en) 2005-08-04
PT1708686E (pt) 2011-04-20
IL176449A (en) 2014-12-31
NO338714B1 (no) 2016-10-03
ATE498395T1 (de) 2011-03-15
BRPI0418228A (pt) 2007-04-27
CA2548915C (en) 2012-10-16
BRPI0418228B1 (pt) 2017-05-23
EA010826B1 (ru) 2008-12-30
DK1708686T3 (da) 2011-05-16
AU2004311880B2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
ME01300B (me) Uglavnom linearne efervescentne oralne dozne forme fentanila i metode davanja
CA2732893C (en) Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers.
US5679685A (en) Accelerated release composition containing bromocriptine
US20010053777A1 (en) Drug treatment for restless leg syndrome
JP2007517054A5 (OSRAM)
CA2549642A1 (en) Effervescent oral opiate dosage forms and methods of administering opiates
JP2013100347A5 (OSRAM)
CA2487699A1 (en) A buffered, liquid nicotine composition for pulmonary administration
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
CA2486859A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
JP5116665B2 (ja) 口腔投与のためのアポモルフィンの薬学的配合物
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
WO2004096118B1 (en) Composition for improving cognition and memory
CN102215811A (zh) 泡腾组合物
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
CA2593094A1 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
MXPA05013295A (es) Derivado sustituido de 1,4-piperidin-4-il-piperazina combinado con un analgesico opioideo y su uso para el tratamiento de dolor y efectos secundarios asociados con tratamientos de base opioidea.
CA2454699A1 (en) Method for treating primary insomnia
JP5134973B2 (ja) 医薬の組み合わせでの処置方法およびこれに適する医薬の組み合わせ
KR20090125748A (ko) 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
US20010034320A1 (en) NK1-receptor antagonists for treating restless legs syndrome
JPWO2020056160A5 (OSRAM)
KR20070085961A (ko) 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도
DK200300110A (da) Pharmaceutical kit for nasal administration